Health Care·Biotechnology·$28.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.89 | N/A | -45.42% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.89 | N/A | -45.42% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current financial performance while highlighting their commitment to long-term growth. They did not provide specific guidance for future quarters.
Management acknowledged challenges in achieving profitability.
They emphasized ongoing investments in growth despite the loss.
Natera's disappointing EPS results indicate ongoing financial challenges, which contributed to a 3.61% drop in stock price. The lack of revenue data and guidance adds uncertainty for investors. Management's focus on growth investments suggests they are prioritizing long-term strategy over short-term profitability.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
WILLIAMS COS INC
Feb 22, 2021